Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recurrence and metastasis are common in
hepatocellular carcinoma
(
HCC
) and correlate with poor prognosis. We investigated the role of
fibronectin type III domain containing 3B
(
FNDC3B
) in
HCC
metastasis. Overexpression of
FNDC3B
in
HCC
cell lines enhanced cell migration and invasion. On the other hand, knockdown of
FNDC3B
using short-hairpin RNA reduced tumor nodule formation in both intra- and extra-hepatic metastasis. High levels of
FNDC3B
were observed in metastatic HCCs and correlated with poor patient survival and shorter recurrence time. Mutagenesis and LC-MS/MS analyses showed that
FNDC3B
promotes cell migration by cooperating with annexin A2 (ANXA2). Furthermore,
FNDC3B
and ANXA2 expression correlated negatively with patient survival. Our results indicate that
FNDC3B
behaves like an oncogene by promoting cell migration. This suggests
FNDC3B
could serve as a biomarker and therapeutic target for
HCC
metastasis.
...
PMID:FNDC3B promotes cell migration and tumor metastasis in hepatocellular carcinoma. 2738 17
Hepatocellular carcinoma
(
HCC
) patients are at high risk for both local recurrence and distant metastasis and tightly associated with poor prognosis. Exploring the molecular mechanism will provide a new opportunity in developing personal treatment for advanced
HCC
patients. As a critical member of the Retinal Determination Gene Network (RDGN), EYA1 has been identified as a tumor promoter in various cancers; however, its role in
HCC
has never been investigated. The present study was aimed to explore the role of EYA1 in
HCC
development. By analyzing public microarray datasets, we found that the
EYA1
mRNA level was enhanced in
HCC
, which was significantly correlated with an aggressive phenotype and poor prognosis. Besides, EYA1 was coordinated with the
fibronectin type III domain containing 3B
(
FNDC3B
) to promote the migration and invasion of
HCC
cells. Western blot assays indicated that EYA1 not only increased the abundance of
FNDC3B
but also contributed to Epithelial-Mesenchymal Transition (EMT)-like phenotype change, like increased N-cadherin and decreased E-cadherin expression. Collectively, this study suggested that EYA1 activated
FNDC3B
to promote the migration and invasion in
HCC
. The aberrant expressions of EYA1 and
FNDC3B
may become the poor predictors for
HCC
patients.
...
PMID:EYA1 promotes cell migration and tumor metastasis in hepatocellular carcinoma. 3110 39
